Monday - July 7, 2025
Calibr-Skaggs Doses First Patient With Switchable CAR-T Cell Therapy in a Phase 1 Trial for Metastatic Breast Cancer
June 19, 2025
LA JOLLA, California, June 19 -- The Scripps Research Institute issued the following news:

* * *

Calibr-Skaggs doses first patient with switchable CAR-T cell therapy in a phase 1 trial for metastatic breast cancer

CLBR001 + ABBV-461 is a novel, investigational, two-part, switchable chimeric antigen T cell (sCAR-T) immunotherapy designed to treat solid tumors.

*

LA JOLLA, CA--The Calibr-Skaggs Institute for Innovative Medicines, the . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products